- Cart 0
- English
Impact Factor 40.4: Absin's Multicolor Kit Ascends to a High-Impact Journal Once Again
PSERP Technology Unlocks the Secrets of Glioma: The "Panoramic View" of the Tumor Microenvironment Is Here!
In the vast cosmos of medical research, glioma has always been the most elusive star. This malignant brain tumor, originating from glial cells, is characterized by its high degree of heterogeneity and complex microenvironment, which has posed significant challenges to countless researchers and clinicians. However, recently, a revolutionary technology—Panoramic Spatial Enhanced Resolution Proteomics (PSERP)—has emerged, lifting a corner of the veil of mystery surrounding glioma.
The study published on May 26, 2025, in the 《Journal of Hematology & Oncology》 (Impact Factor 40.4) by the team of Professor Chen Gong from Zhongshan Hospital, Fudan University, and the team of Professor Yang Wenjun from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, has brought us a feast of scientific research. Their development of the PSERP technology is akin to taking a high-definition "panoramic photograph" of the tumor microenvironment. It allows us to see, with unprecedented clarity, the differences in protein expression across various regions within the tumor and how these differences influence tumor growth and metastasis.
It is worth mentioning with delight that the key technology that unveiled this mechanism is precisely the Multiplex Fluorescent Immunohistochemistry Kit provided by Absin, with the catalog number #abs50014
Source of the Original Article
Research Objectives
Primary Objective: To develop a novel method, Panoramic Spatial Enhanced Resolution Proteomics (PSERP), capable of rapidly analyzing the spatial heterogeneity of proteomics at submillimeter resolution across entire tissue sections, and to apply this method to the study of glioma in order to elucidate the tumor heterogeneity and the complexity of the tumor microenvironment.
Specific Objectives: Through the PSERP method, to identify and quantify differences in protein expression between malignant and non-malignant regions within glioma, revealing the protein distribution patterns from the tumor core to the tumor edge and non-malignant areas, and exploring their relationships with tumor heterogeneity and cellular characteristics. Additionally, to integrate single-cell transcriptomic data to elucidate the spatial context of cellular composition and intercellular communication, and to explore the spatial expression patterns of tumor-specific peptides, potentially providing targets for future immunotherapies.
Experimental Techniques
The PSERP method integrates tissue expansion, automated sample segmentation, trypsin digestion, and high-throughput proteomic analysis. Tissue expansion technology is employed to physically enlarge the tissue while preserving protein localization. Subsequently, a custom 3D-printed cutting tool is used to precisely segment the expanded tissue into thousands of “voxels.” These voxels are then transferred to a 96-well plate, with their spatial coordinates recorded. Gel-based digestion and peptide extraction are performed next. Finally, comprehensive spatial proteomic analysis is carried out using high-throughput data-independent acquisition (DIA) liquid chromatography–tandem mass spectrometry (LC-MS/MS).
Single-Cell Transcriptomics Analysis: Single-cell nuclear RNA sequencing was performed on the same glioma samples to obtain gene expression information at the single-cell level, which was used for subsequent integrative analysis with spatial proteomics data.
Multicolor Immunohistochemistry (mIHC): Used to detect the expression and localization of specific proteins within tissues. For instance, the study employed mIHC to stain CSF1R+ tumor-associated macrophages (TAMs) and EGFR+ tumor cells to observe their distribution in IDH1-WT/EGFR-mutant samples. Through mIHC staining, the spatial distribution of different cell types within the tissue can be visually observed, providing cellular-level validation and supplementation for the PSERP data.
Spatial Transcriptomics Technologies: Such as Stereo-seq, SeqScope, and PIXEL-seq, which are used to analyze the expression of transcripts in an unbiased and panoramic manner.
Spatial Genomics Technologies: Such as spatial ATAC-seq, which involves in situ Tn5 transposition and probe ligation on a microfluidic device, followed by digestion and sequencing, to analyze chromatin accessibility.
Spatial Metabolomics Technologies: Such as MALDI-IMS (Matrix-Assisted Laser Desorption/Ionization Imaging Mass Spectrometry), which is used to reveal the spatial distribution and molecular interactions of metabolites.
Conclusions
Effectiveness of the PSERP Method: The PSERP method is capable of rapidly quantifying the spatial variability of proteomics across entire tissue sections with submillimeter resolution, identifying over 10,000 proteins. It offers a novel perspective and tool for studying tumor heterogeneity and cellular characteristics.
Proteomic Features of Glioma: The study revealed significant proteomic differences between malignant and non-malignant regions across various glioma samples (including IDH1-WT/EGFR-mutant, IDH1-mutant, and IDH1/EGFR double wild-type). Proteins expressed in malignant regions are closely associated with tumor-related pathways such as cell proliferation, metabolic reprogramming, and DNA repair, while non-malignant regions exhibit features of immune cell infiltration and metabolic pathways.
Complexity of the Tumor Microenvironment: By integrating PSERP data with single-cell transcriptomic data, the spatial characteristics of cellular composition and intercellular communication within the glioma microenvironment were elucidated. For example, the enrichment of TAMs at the tumor boundary may promote tumor cell growth via the EGF-EGFR signaling pathway, while the enrichment of neuronal cells in the non-malignant regions of IDH1-mutant samples may reduce inflammation by inhibiting the NLRP3 inflammasome.
Spatial Expression of Tumor-Specific Peptides: The PSERP method also includes a spatially resolved workflow for identifying tumor-specific peptides, revealing their spatial expression patterns in glioma samples of different genotypes. This provides potential targets for future immunotherapies. For instance, combining tumor-specific peptides may enhance the efficacy of immunotherapy in patient-derived cells (PDCs) and patient-derived xenograft (PDX) models.
Clinical Application Prospects: The PSERP method offers new insights into the molecular landscape of tumors, paving the way for future precision medicine and targeted immunotherapies.
|
CatalogNumber |
Product Name |
Specification |
|
Absin 2-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
100T |
|
|
Absin 2-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
100T |
|
|
Absin 3-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
100T |
|
|
Absin 3-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
100T |
|
|
Absin 3-Color IHC Kit B (Anti-Rabbit Secondary Antibody) |
100T |
|
|
Absin 3-Color IHC Kit B (Anti-Rabbit and Mouse Secondary Antibody) |
100T |
|
|
Absin 4-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 4-Color IHC Kit(Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 4-Color IHC Kit B (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 4-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 5-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 5-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 6-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 6-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 6-Color IHC Kit (Plus) (Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 6-Color IHC Kit (plus) (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 7-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 7-Color IHC Kit(Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 7-Color IHC Kit (Anti-Rabbit and Mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 7-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 7-Color IHC Kit (Anti-Rabbit Secondary Antibody) |
20T/50T/100T |
|
|
Absin 7-Color IHC Kit (Anti-Rabbit&mouse Secondary Antibody) |
20T/50T/100T |
|
|
Absin 10-Color IHC Kit |
100T |
|
|
Lung Cancer Tumor Microenvironment mIHC Detection Kit (I) |
20T |
|
|
Lung Cancer Tumor Microenvironment mIHC Detection Kit (II) |
20T |
Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.
|
Absin Bioscience Inc. Email: worldwide@absin.net |
 Follow us on Facebook: Absin Bio |
July 22, 2025
Clicks：94
